Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Approaches to Treating Multiple Myeloma, Now and Moving Forward.

Gupta VA, Joseph NS, Nooka AK.

JCO Oncol Pract. 2020 Jan;16(1):15-16. doi: 10.1200/JOP.19.00560. No abstract available.

PMID:
32039661
2.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W.

Blood Adv. 2020 Jan 14;4(1):181-190. doi: 10.1182/bloodadvances.2019000491.

3.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD.

Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.

PMID:
31859245
4.

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.

Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, Dhodapkar MV, Gupta VA, Jaye DL, Wu J, Goyal S, Chen Z, Boise LH, Lonial S, Nooka AK, Kaufman JL.

Blood Cancer J. 2019 Nov 25;9(12):94. doi: 10.1038/s41408-019-0254-0.

5.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
6.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA.

Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.

7.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S.

Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

PMID:
31090928
8.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH.

Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.

9.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV.

JCI Insight. 2019 Apr 23;5. pii: 127807. doi: 10.1172/jci.insight.127807.

10.

Daratumumab in multiple myeloma.

Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S.

Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5. Review.

PMID:
30951198
11.

Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma.

Nooka AK, Lonial S.

Cancer J. 2019 Jan/Feb;25(1):19-31. doi: 10.1097/PPO.0000000000000354.

PMID:
30694856
12.

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.

Matulis SM, Gupta VA, Neri P, Bahlis NJ, Maciag P, Leverson JD, Heffner LT Jr, Lonial S, Nooka AK, Kaufman JL, Boise LH.

Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24. No abstract available.

13.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S.

Blood Cancer J. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8.

14.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.

Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW.

Nat Commun. 2018 Dec 17;9(1):5341. doi: 10.1038/s41467-018-07551-w.

15.

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK.

Cancer. 2019 Jan 15;125(2):185-193. doi: 10.1002/cncr.31677. Epub 2018 Nov 27.

16.

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK.

Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.

17.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.

Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.

Cancer. 2019 Feb 1;125(3):416-423. doi: 10.1002/cncr.31718. Epub 2018 Oct 17.

18.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

19.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.

20.

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.

Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK.

Future Oncol. 2018 Dec;14(30):3111-3121. doi: 10.2217/fon-2018-0275. Epub 2018 Aug 23. Review.

PMID:
30136602
21.

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS.

JAMA Oncol. 2018 Dec 1;4(12):e183267. doi: 10.1001/jamaoncol.2018.3267. Epub 2018 Dec 13.

22.

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.

Chang A, Nasti TH, Khan MK, Parashar S, Kaufman JL, Boise LH, Lonial S, Ahmed R, Nooka AK.

J Oncol Pract. 2018 Sep;14(9):561-564. doi: 10.1200/JOP.18.00208. Epub 2018 Jul 13. No abstract available.

PMID:
30004825
23.

Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S.

J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143. Review.

PMID:
29996069
24.

CD86 regulates myeloma cell survival.

Gavile CM, Barwick BG, Newman S, Neri P, Nooka AK, Lonial S, Lee KP, Boise LH.

Blood Adv. 2017 Nov 16;1(25):2307-2319. doi: 10.1182/bloodadvances.2017011601. eCollection 2017 Nov 28.

25.

TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.

Shah SP, Nooka AK, Lonial S, Boise LH.

Blood Adv. 2017 Sep 26;1(21):1848-1853. doi: 10.1182/bloodadvances.2017006122. eCollection 2017 Sep 26.

26.

Development of GLUT4-selective antagonists for multiple myeloma therapy.

Wei C, Bajpai R, Sharma H, Heitmeier M, Jain AD, Matulis SM, Nooka AK, Mishra RK, Hruz PW, Schiltz GE, Shanmugam M.

Eur J Med Chem. 2017 Oct 20;139:573-586. doi: 10.1016/j.ejmech.2017.08.029. Epub 2017 Aug 14.

27.

High-risk Multiple Myeloma: Definition and Management.

Joseph NS, Gentili S, Kaufman JL, Lonial S, Nooka AK.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S80-S87. doi: 10.1016/j.clml.2017.02.018. Review.

PMID:
28760306
28.

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2. Erratum in: Leukemia. 2018 Oct;32(10):2305.

29.

Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, Patel SR, Yee M, Fasano RM, Josephson CD, Kaufman RM, Roback JD, Lonial S, Stowell SR.

Blood. 2017 Jun 1;129(22):3033-3037. doi: 10.1182/blood-2016-11-749432. Epub 2017 Apr 3. No abstract available.

30.

Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.

Shah NN, McClellan W, Flowers CR, Lonial S, Khoury H, Waller EK, Langston A, Nooka AK.

Infect Control Hosp Epidemiol. 2017 Jun;38(6):651-657. doi: 10.1017/ice.2017.12. Epub 2017 Mar 23.

PMID:
28330512
31.

Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH.

Blood. 2017 Apr 6;129(14):1969-1979. doi: 10.1182/blood-2016-10-745059. Epub 2017 Feb 1.

32.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators.

N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.

33.

Is Maintenance Therapy for Everyone?

Nooka AK, Lonial S.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S139-44. doi: 10.1016/j.clml.2016.02.011. Review.

PMID:
27521311
34.

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.

Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH.

Oncotarget. 2016 Sep 13;7(37):59727-59741. doi: 10.18632/oncotarget.10847.

35.

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.

DeFilipp Z, Rosand CB, Goldstein DA, Master VA, Carthon BC, Harris WB, Kucuk O, Al-Kadhimi Z, Cohen JB, Flowers CR, Lechowicz MJ, Nooka AK, Kaufman JL, Langston AA, Chen Z, Arora J, Waller EK.

Bone Marrow Transplant. 2017 Jan;52(1):132-134. doi: 10.1038/bmt.2016.189. Epub 2016 Jul 18. No abstract available.

PMID:
27427922
36.

Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation.

Nooka AK, Behera M, Lonial S, Dixon MD, Ramalingam SS, Pentz RD.

Cancer. 2016 Oct 15;122(20):3207-3214. doi: 10.1002/cncr.30090. Epub 2016 Jul 12.

37.

New Targets and New Agents in High-Risk Multiple Myeloma.

Nooka AK, Lonial S.

Am Soc Clin Oncol Educ Book. 2016;35:e431-41. doi: 10.14694/EDBK_159516. Review.

38.

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, Nooka AK, Kaufman JL, Lonial S, Boise LH.

Cancer Biol Ther. 2016 Jul 2;17(7):769-77. doi: 10.1080/15384047.2016.1192086.

39.

Death by a thousand cuts: the slow demise of chemotherapy.

Nooka AK, Lonial S.

Cancer. 2016 Jul 1;122(13):1971-3. doi: 10.1002/cncr.30024. Epub 2016 May 18. No abstract available.

40.

Novel Combination Treatments in Multiple Myeloma.

Nooka AK, Lonial S.

Oncology (Williston Park). 2016 May;30(5):451-65. Review.

41.

Myeloma Is Not a Single Disease.

Lonial S, Nooka AK.

J Oncol Pract. 2016 Apr;12(4):287-92. doi: 10.1200/JOP.2016.010926. Review.

PMID:
27072380
42.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ.

Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. Epub 2016 Apr 24.

43.

Meningeal Myelomatosis.

DeFilipp Z, Sahovic EA, Nooka AK.

J Oncol Pract. 2016 Feb;12(2):187-8. doi: 10.1200/JOP.2015.010009. No abstract available.

PMID:
26869657
44.

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.

Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, Leleu X, Rasche L, Nooka AK, Druzd-Sitek A, Walewski J, Davila J, Caers J, Maisnar V, Gertz M, Gentile M, Fantl D, Mele G, Vesole DH, Yee AJ, Shustik C, Lentzsch S, Zweegman S, Gozzetti A, Skotnicki AB, Castillo JJ.

Leuk Lymphoma. 2016 Sep;57(9):2071-6. doi: 10.3109/10428194.2015.1128542. Epub 2016 Jan 4.

PMID:
26726867
45.

Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital.

Yun HD, Dossul T, Bernal-Mizrachi L, Switchenko J, Ndibe C, Ibraheem A, Dixon MD, Langston AA, Nooka AK, Flowers CR, Pentz RD, Waller EK.

J Stem Cell Res Ther. 2016;6. pii: 328. doi: 10.4172/2157-7633.1000328. Epub 2016 Feb 19.

46.

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.

Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S, Boise LH.

Leukemia. 2016 May;30(5):1086-93. doi: 10.1038/leu.2015.350. Epub 2015 Dec 28.

47.

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.

Bajpai R, Matulis SM, Wei C, Nooka AK, Von Hollen HE, Lonial S, Boise LH, Shanmugam M.

Oncogene. 2016 Jul 28;35(30):3955-64. doi: 10.1038/onc.2015.464. Epub 2015 Dec 7.

48.

Novel combination approaches for myeloma.

Lonial S, Nooka AK.

Hematology Am Soc Hematol Educ Program. 2015;2015:286-93. doi: 10.1182/asheducation-2015.1.286. No abstract available.

PMID:
26637735
49.

In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.

Mishra RK, Wei C, Hresko RC, Bajpai R, Heitmeier M, Matulis SM, Nooka AK, Rosen ST, Hruz PW, Schiltz GE, Shanmugam M.

J Biol Chem. 2015 Jun 5;290(23):14441-53. doi: 10.1074/jbc.M114.628826. Epub 2015 Apr 6.

50.

Treatment options for relapsed and refractory multiple myeloma.

Nooka AK, Kastritis E, Dimopoulos MA, Lonial S.

Blood. 2015 May 14;125(20):3085-99. doi: 10.1182/blood-2014-11-568923. Epub 2015 Apr 2. Review.

PMID:
25838342

Supplemental Content

Loading ...
Support Center